We Believe Healthcare's Next Biotech Buyout Target Is…
Which biotech company will be the next buyout target? To answer this question, we turned to three of our healthcare contributors, and this is what they had to say.
Here's Why Exelixis' Stock Briefly Gained 10% Today
Swiss regulatory approval for Exelixis' experimental skin cancer treatment drove the biotech's shares higher today.